Individualized cell therapy using patient-derived antigen-specific regulatory t cells
TW202641828APending Publication Date: 2026-10-16PHAIM PHARMA LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW115126603
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-17
- Filing Date
- 2022-06-16
- Publication Date
- 2026-10-16
Abstract
Compositions containing one or more peptide fragments of proinsulin for the treatment of autoimmune diseases of type 1 diabetes mellitus (T1DM), methods of using these compositions to treat autoimmune diseases of T1DM, and kits containing these compositions for the diagnosis and / or treatment of autoimmune diseases of T1DM. Compositions comprising one or more peptide fragments of preproinsulin for treating type 1 diabetes mellitus (T1DM) autoimmunity, methods of treating T1DM autoimmunity using such compositions, and kits comprising such compositions for diagnosing and / or treating T1DM autoimmunity.
Need to check novelty before this filing date? Find Prior Art
